ArticleEuroasian journal of hepato-gastroenterology
Incidence and Outcome of HTG-AP at a Tertiary Care Center in Eastern India: A Retrospective Analysis.
Article in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertriglyceridemia-associated pancreatitis (HTG-AP) is a notable cause of acute pancreatitis (AP) due to high triglyceride (TG) levels. It is associated with more complications than non-hypertriglyceridemia-associated acute pancreatitis (non-HTG AP). Current treatments include supportive care, insulin infusion, and plasmapheresis. Improved guidelines and protocols are needed due to the complex nature and rarity of the condition. The current study was conducted because of the paucity of data available for HTG-AP from India. Materials and methods: The study retrospectively analyzed data of adult HTG-AP patients hospitalized at a tertiary care facility in Eastern India from August 2021 to August 2024. Acute pancreatitis was classified per modified Atlanta criteria, with HTG-AP defined as AP associated with a serum TG > 1000 mg/dL. The primary outcome was a > 50% decline in TG level from the baseline. Secondary outcomes included complete cessation of insulin therapy once the TG level < 500 mg/dL, adverse events, and in-hospital mortality. Results: Twenty-four patients had HTG-AP (median age: 38.5 years; 87.5% male), accounting for 5.7% of all AP admissions. Diabetes and alcohol use were each present in 62.5% of cases. About 62.5% of patients had moderately severe to severe AP, which was significantly higher than non-HTG-AP cases. Necrotizing pancreatitis was observed in 45.8% of patients. Insulin therapy reduced TG levels by more than 50% in 45.83%, 87.5%, and 91.67% of the patients at 24, 48, and 72 hours, respectively. Insulin therapy could be stopped in 25%, 62.5%, and 83.3% of the patients at 24, 48, and 72 hours, respectively. Only one patient had symptomatic hypoglycemia, which was managed with a dextrose bolus. In-hospital mortality was seen in 12.5% of the cases. Conclusion: About 5.7% of the Indian patients admitted with AP had HTG-AP, with about two-thirds having non-mild AP. Insulin infusion was the primary treatment for lowering serum TG levels in most patients with HTG-AP, with a fourth to a fifth of the patients achieving control of their TG levels. How to cite this article: Giri S, Singh RK, Jena SK,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.